NVSNovartis PharmaceuticalsSigning up patients
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Somatostatin Receptor Positive (SSTR+) · Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 240 (planned)
- Started
- May 30, 2025
- Main results expected
- Dec 8, 2028
- Fully finished
- Jan 23, 2034
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) centrally assessed by Blinded Independent Review Committee (BIRC)
Measured over: After observing approximately 88 PFS events as per BIRC assessments, expected after approximately 33 months from study start
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06784752 · record last updated 2026-09-11 · checked 2026-11-09 15:47 UTC